Targets › VEGFA
54 programs from 45 companies in 349 trials: 195 Phase 2, 83 Phase 3, 50 Phase 1, 21 Phase 4; Oncology, Ophthalmology, Metabolic and endocrine; next expected readout Dec 2026.
[N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death (By similarity)..; FUNCTION: [VEGFA]: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces…. (UniProt, P15692)
Open in Phaseline: the race on VEGFA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Faricimab Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor | ANGPT2, VEGFA | Phase 4 | Diabetic Macular Edema | Jan 2027 |
| Amur State Medical Academy | Deoxyribonucleic acid supercoiled plasmid pCMV-VEGF165 (Neovasculgen) VEGF gene therapy - plasmid DNA encoding vascular endothelial growth factor 165 | VEGFA | Phase 4 | Severe Lower Limb Ischemia | May 2027 |
| Roche | Faricimab Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor | ANGPT2, VEGFA | Phase 4 | Neovascular Age-related Macular Degeneration (nAMD); Wet Age-related Macular Degeneration; Diabetic Macular Edema; Macular Degeneration Choroidal Neovascularization … | Sep 2027 |
| Guangdong Provincial People's Hospital | Brolucizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 4 | Diabetic Macular Edema | – |
| Shanghai Eye Disease Prevention and Treatment Center | Conbercept Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor | VEGFA, VEGFB, PGF, VEGFC | Phase 4 | Diabetic Macular Edema | – |
| AbbVie | ABBV-RGX-314 (surabgene lomparvovec, RGX-314) AAV8 vector containing a transgene for anti-VEGF Fab | VEGFA | Phase 3 | AMD; Neovascular Age-related Macular Degeneration; Diabetic Retinopathy (DR); Neovascular Age-Related Macular Degeneration (nAMD) … | Dec 2026 |
| AstraZeneca | Bevacizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Hepatocellular Carcinoma; Advanced Ovarian Cancer; Hepatocellular Carcinoma (HCC); Keloids … | Dec 2026 |
| Biotheus | PM8002 bispecific antibody targeting PD-L1 and VEGF | CD274, VEGFA, PDCD1LG2 | Phase 3 | SCLC; Triple Negative Breast Cancer(TNBC); NSCLC; Neuroendocrine Neoplasm … | Jan 2027 |
| Regeneron Pharmaceuticals | Aflibercept Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 3 | Neovascular Age-Related Macular Degeneration; Diabetic Maculopathy; Diabetic Macular Edema (DME); Proliferative Diabetic Retinopathy (PDR) … | Jan 2027 |
| Roche | Ranibizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD); Neovascular Age-related Macular Degeneration; Diabetic Macular Edema; Neovascular Age-Related Macular Degeneration … | Feb 2027 |
| Innovent Biologics (Suzhou) | IBI302 Anti-VEGF monoclonal antibody | VEGFA | Phase 3 | Neovascular Age-related Macular Degeneration | Feb 2027 |
| 4D Molecular Therapeutics | 4D-150 AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s | VEGFA, VEGFC, VEGFR2 | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema … | Mar 2027 |
| JSC NextGen | Neovasculgen® Plasmid DNA encoding vascular endothelial growth factor A (VEGF-A) | VEGFA | Phase 3 | Ulcer Foot; IC | Mar 2027 |
| Akeso | AK112 (Ivonescimab) Dual PD-1/TIGIT bispecific antibody | PDCD1, VEGFA | Phase 3 | Pancreatic Cancer; Non-Small Cell Lung Cancer; Platinum-sensitive Ovarian Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) | May 2027 |
| Alvotech Swiss | AVT29 VEGF-A inhibitor (proposed aflibercept HD biosimilar) | VEGFA | Phase 3 | Diabetic Macular Edema | Jul 2027 |
| Roche | Bevacizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Hepatocellular Carcinoma; Advanced Liver Cancers | Jul 2027 |
| Amgen | ABP 938 Anti-VEGF monoclonal antibody | VEGFA | Phase 3 | Neovascular Age-related Macular Degeneration | Jul 2027 |
| Outlook Therapeutics | Bevacizumab (ONS-5010) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Age-Related Macular Degeneration | Dec 2027 |
| Innostellar Biotherapeutics | LX102 AAV-based gene therapy encoding VEGF-trap (soluble VEGF receptor fusion protein) | VEGFA | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular Degeneration | Mar 2028 |
| Belfast Health and Social Care Trust | brolucizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Severe Diabetic Macular Oedema | Nov 2028 |
| Shanghai Pulmonary Hospital, Shanghai, China | PD-L1/VEGF Bispecific Antibody (PM8002) PD-L1 and VEGF dual-targeting bispecific antibody | CD274, VEGFA | Phase 3 | Locally Advanced Non-Small Cell Lung Cancer | Dec 2033 |
| Prestige Biopharma | Bevacizumab (HD204) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 3 | Lung Cancer | – |
| Jiangsu Simcere Pharmaceutical | ENDOSTAR Recombinant human endostatin; antiangiogenic agent and vascular endothelial growth factor | VEGFA | Phase 3 | Malignant Pleural Effusion | – |
| Shandong Suncadia Medicine | Bevacizumab (BP102) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Advanced Malignant Tumour | Dec 2026 |
| Shanghai Henlius Biotech | Bevacizumab (HLX04) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Metastatic Colorectal Cancer; Carcinoma, Hepatocellular | Dec 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | PD-1/VEGF dual antibody PD-1 inhibitor and anti-VEGF antibody | PDCD1, VEGFA, CTLA4 | Phase 2 | Glioblastoma | Jan 2027 |
| ARCAGY/ GINECO GROUP | Bevacizumab-Awwb (MVASI) Anti-VEGF monoclonal antibody | VEGFA | Phase 2 | Ovarian Cancer | Feb 2027 |
| Jiangsu HengRui Medicine | Bevacizumab (BP102) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Lung Cancer | Nov 2027 |
| Sierra Eye Associates | RGX-314 Dose 1 AAV8 vector encoding anti-VEGF Fab | VEGFA | Phase 2 | Diabetic Macular Edema | Dec 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Ivonescimab (AK112) Bispecific monoclonal antibody targeting PD-1 and VEGF | PDCD1, VEGFA | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2027 |
| Zhejiang Cancer Hospital | Endostar Recombinant human endostatin; anti-angiogenic agent targeting VEGF signaling | VEGFA | Phase 2 | Nasopharyngeal Carcinoma | Jun 2028 |
| Swiss Cancer Institute | Ivonescimab Bispecific PD-1/VEGF antibody | PDCD1, VEGFA | Phase 2 | NSCLC | Jul 2028 |
| PPD Development, LP | bevacizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Jul 2028 |
| Adverum Biotechnologies | ADVM-022 AAV gene therapy expressing aflibercept (VEGF inhibitor) | VEGFA | Phase 2 | Neovascular Age-related Macular Degeneration | Aug 2028 |
| Suzhou Suncadia Biopharmaceuticals | Bevacizumab (BP102) Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Malignant Solid Tumors | Dec 2028 |
| VA Office of Research and Development | Itraconazole Cytochrome P450 51 inhibitor | SMO, AKT1, VEGFA | Phase 2 | Esophageal Adenocarcinoma | Apr 2029 |
| Koen Rovers | CAPOX-bevacizumab Oxaliplatin and capecitabine with anti-VEGF monoclonal antibody | VEGFA | Phase 2 | Colorectal Neoplasm | Jun 2029 |
| Koen Rovers | FOLFIRI-bevacizumab Irinotecan, 5-fluorouracil, and leucovorin with anti-VEGF monoclonal antibody | VEGFA | Phase 2 | Colorectal Neoplasm | Jun 2029 |
| Koen Rovers | FOLFOX-bevacizumab Oxaliplatin, 5-fluorouracil, and leucovorin with anti-VEGF monoclonal antibody | VEGFA | Phase 2 | Colorectal Neoplasm | Jun 2029 |
| Ashvattha Therapeutics | Aflibercept (D-4517) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 2 | Neovascular Age-related Macular Degeneration | – |
| Samsung Bioepis | Aflibercept (SB15) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 2 | Neovascular Age-related Macular Degeneration | – |
| Chengdu Origen Biotechnology | KH631 AAV vector-based gene therapy expressing anti-VEGF protein | VEGFA | Phase 1 | Age-Related Macular Degeneration | Dec 2026 |
| Chengdu Origen Biotechnology | KH658 AAV vector delivering anti-VEGF protein | VEGFA | Phase 1 | Age-related Macular Degeneration; Age-Related Macular Degeneration | Dec 2026 |
| Avirmax Biopharma | ABI-110 AAV2-delivered VEGF Trap | VEGFA | Phase 1 | Neovascular (Wet) AMD | Jan 2027 |
| OncoC4 | AI-081 Bispecific antibody targeting PD-1 and VEGF | PDCD1, VEGFA | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| Unlimited Biotechnology | VEGF Plasmid Intramuscular plasmid DNA encoding vascular endothelial growth factor to induce angiogenes | VEGFA | Phase 1 | Age-related Muscle Decline | Sep 2027 |
| Eyconis INC. | EYC-0305 Anti-VEGF monoclonal antibody or VEGF-binding protein with extended-delivery formulation | VEGFA | Phase 1 | Neovascular (Wet) Age-Related Macular Degeneration | May 2028 |
| Jiangsu Simcere Pharmaceutical | SIM0689 for Injection PD-1/VEGF bispecific antibody | PDCD1, VEGFA | Phase 1 | Neoplasms, Malignant | Dec 2028 |
| Eli Lilly | AAVAnc80-antiVEGF AAV-mediated anti-VEGF gene therapy | VEGFA | Phase 1 | Vestibular Schwannoma | Aug 2029 |
| AP Biosciences | AP505 Anti-PD-L1 and Anti-VEGF antibody fusion protein | CD274, VEGFA | Phase 1 | Advanced Solid Tumors | – |
| Institute of Automation, Chinese Academy of Sciences | Bev-ICG VEGF-A targeting fluorescent probe (bevacizumab conjugated to indocyanine green) | VEGFA | Phase 1 | Gastrointestinal Carcinoma | – |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | IMM2510 Anti-PD-L1/VEGF bispecific antibody fusion protein | CD274, VEGFA | Phase 1 | Advanced Solid Tumors | – |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Intrastromal anti-VEGF injection Vascular Endothelial Growth Factor (VEGF) inhibition | VEGFA | Phase 1 | Herpes Simplex Keratitis | – |
| Lomonosov Moscow State University Medical Research and Educational Center | MediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparatio Human mesenchymal stromal cell secretome containing vascular endothelial growth factor (VE | VEGFA | Phase 1 | Azoospermia, Nonobstructive | – |
Hepatocellular Carcinoma (22) Neovascular Age-related Macular Degeneration (11) Hepatocellular Carcinoma (HCC) (10) Colorectal Cancer (10) Metastatic Colorectal Cancer (9) Diabetic Macular Edema (8) Glioblastoma (7) Ovarian Cancer (7) Colorectal Cancer Metastatic (5) Lung Cancer (4) Neovascular Age-Related Macular Degeneration (4) Severe Diabetic Macular Oedema (4)
antibody (19), small molecule (15), mixed (13), other (6), protein or peptide (1)
Roche (4) Second Affiliated Hospital, Zhejiang University, School of Medicine (3) Koen Rovers (3) Jiangsu Simcere Pharmaceutical (2) Chengdu Origen Biotechnology (2) Sierra Eye Associates (1) Biotheus (1) Amur State Medical Academy (1) Lomonosov Moscow State University Medical Research and Educational Center (1) AstraZeneca (1) Prestige Biopharma (1) Belfast Health and Social Care Trust (1) Institute of Automation, Chinese Academy of Sciences (1) Swiss Cancer Institute (1) Avirmax Biopharma (1) Eli Lilly (1) 4D Molecular Therapeutics (1) JSC NextGen (1) PPD Development, LP (1) Shanghai Henlius Biotech (1)
PDCD1 (6) CD274 (4) PGF (4) VEGFC (2) ANGPT2 (2) PDCD1LG2 (1) VEGFR2 (1) VEGFB (1) CTLA4 (1) SMO (1) AKT1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.